Huang Jane
SEC CIK 1683913 · EDGAR
BoughtSold
Most active insiders at PRLD, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Bonita David P | Dir, 10% | $12.50M | — |
| 2 | ORBIMED ADVISORS LLC | Dir, 10% | $12.50M | — |
| 3 | Huang Jane | Pres, CMO | — | — |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 10% | — | — |
Transactions 36
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-07 | 2025-10-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 90.3K | +12% | — |
| D | 2025-10-07 | 2025-10-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | F - Tax | $1.47 | -3,355 | 86.9K | -4% | -$4,932 |
| D | 2025-07-08 | 2025-07-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 84.3K | +13% | — |
| D | 2025-07-08 | 2025-07-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | F - Tax | $0.79 | -3,355 | 80.9K | -4% | -$2,650 |
| D | 2025-04-07 | 2025-04-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | F - Tax | $0.68 | -3,355 | 74.9K | -4% | -$2,281 |
| D | 2025-04-07 | 2025-04-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 78.2K | +14% | — |
| D | 2025-01-07 | 2025-01-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 72.7K | +15% | — |
| D | 2025-01-07 | 2025-01-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | F - Tax | $1.39 | -3,859 | 68.9K | -5% | -$5,364 |
| D | 2024-10-07 | 2024-10-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | F - Tax | $2.00 | -3,349 | 63.3K | -5% | -$6,698 |
| D | 2024-10-07 | 2024-10-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 66.7K | +16% | — |
| D | 2024-07-08 | 2024-07-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 60.7K | +18% | — |
| D | 2024-07-08 | 2024-07-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | F - Tax | $3.60 | -3,347 | 57.3K | -6% | -$12.0K |
| D | 2024-04-08 | 2024-04-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 54.6K | +21% | — |
| D | 2024-04-08 | 2024-04-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | F - Tax | $4.74 | -3,347 | 51.3K | -6% | -$15.9K |
| D | 2024-01-08 | 2024-01-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 49.1K | +24% | — |
| D | 2024-01-08 | 2024-01-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | F - Tax | $3.77 | -3,844 | 45.3K | -8% | -$14.5K |
| D | 2023-10-06 | 2023-10-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 39.7K | +31% | — |
| D | 2023-07-06 | 2023-07-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +9,375 | 33.6K | +39% | — |
| D | 2023-07-06 | 2023-07-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | F - Tax | $4.65 | -3,242 | 30.4K | -10% | -$15.1K |
| D | 2023-04-06 | 2023-04-06 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | S - Sale+OE | $6.12 | -13.3K | 24.2K | -35% | -$81.3K |
| D | 2023-04-06 | 2023-04-04 | PRLD | Prelude Therapeutics Inc | Huang Jane | Pres, CMO | M - OptEx | — | +37.5K | 37.5K | New | — |
| DM | 2021-12-16 | 2021-12-14 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | S - Sale+OE | $278.14 | -1,500 | 400 | -79% | -$417.2K |
| D | 2021-12-16 | 2021-12-14 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | M - OptEx | $119.96 | +1,500 | 1,500 | New | +$179.9K |
| M | 2021-12-02 | 2021-11-30 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | A - Grant | $0.00 | +15.9K | 1,049 | New | $0 |
| M | 2021-12-02 | 2021-12-01 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | S - Sale | $359.86 | -1,049 | 519 | -67% | -$377.5K |
| D | 2021-11-19 | 2021-11-17 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | M - OptEx | $119.96 | +1,500 | 1,500 | New | +$179.9K |
| DM | 2021-11-19 | 2021-11-17 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | S - Sale+OE | $381.34 | -1,500 | 400 | -79% | -$572.0K |
| DM | 2021-10-21 | 2021-10-19 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | S - Sale+OE | $372.78 | -1,500 | 1,200 | -56% | -$559.2K |
| D | 2021-10-21 | 2021-10-19 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | M - OptEx | $119.96 | +1,500 | 1,500 | New | +$179.9K |
| D | 2021-09-22 | 2021-09-20 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | M - OptEx | $119.96 | +6,000 | 6,000 | New | +$719.8K |
| DM | 2021-09-22 | 2021-09-20 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | S - Sale+OE | $397.96 | -6,000 | 5,900 | -50% | -$2.39M |
| M | 2021-09-15 | 2021-09-13 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | S - Sale | $358.14 | -12.9K | 1,582 | -89% | -$4.62M |
| M | 2021-09-02 | 2021-08-31+ | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | A - Grant | $0.00 | +15.4K | 305.8K | +5% | $0 |
| M | 2021-09-02 | 2021-09-01+ | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | S - Sale | $318.88 | -1,087 | 0 | -100% | -$346.6K |
| DM | 2021-07-19 | 2021-07-15 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | M - OptEx | $146.90 | +21.0K | 6,914 | New | +$3.09M |
| DM | 2021-07-19 | 2021-07-15 | ONC | BeOne Medicines Ltd. | Huang Jane | CMO, Hematology | S - Sale+OE | $332.42 | -21.0K | 0 | -100% | -$6.98M |
Purchase Sale Sale after option exercise All abbreviations